BioStack Platforms

Look, if you're building bio AI models and you're still scrambling across fragmented sources for clean proteomics or perturbation data, BioStack is solving a real problem that wastes real time and money. Their move here is the continuous ADMET/Tox data generation cycles — that's genuinely useful because that testing loop is traditionally the slowest and most expensive part of drug development, and having it automated as part of your training pipeline changes the math on model quality. The 8X cost savings for Big Pharma and sub-24-hour deployment for universities are specific enough to take seriously, but I'm low-key curious what their actual dataset breadth looks like in production versus the pitch deck — this market has a lot of "high quality" claims. Worth a closer look if you're in biotech AI and bleeding money on data acquisition right now.